-
Exploratory Efficacy Data Suggests Further Study of Peanut Tolerance with Oral Mucosal Immunotherapy (OMIT)
NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) — Intrommune Therapeutics, Inc., a clinical-stage biotechnology company committed to developing a patient-friendly treatment platform for people with peanut and other food allergies, today announced the presentation of exploratory efficacy data from the Oral Mucosal Escalation Goal Assessment (OMEGA) Phase 1 safety trial at the 2026 Eastern Allergy…
-
NatureU® Now Has Three Clinical Studies Publicly Registered on ClinicalTrials.gov as 56-Day PQQ Skin-Aging Study (NCT07571629) Joins Two Previously Published Peer-Reviewed Trials
Kwun Tong, Kowloon, HK, June 05, 2026 (GLOBE NEWSWIRE) — The newly registered 56-day exploratory study of NatureU® Mind Care BeautyU Caps — reporting within-participant changes of −46.7% in crow’s-feet wrinkle count and +58.7% in stratum corneum hydration at Day 56 — joins NatureU’s prior sleep and satiety clinical trials, both already published in peer-reviewed…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.